Insulin-like growth factor-I concentration and risk of prostate cancer: Results from the European prospective investigation into cancer and nutrition Journal Article


Authors: Price, A. J.; Allen, N. E.; Appleby, P. N.; Crowe, F. L.; Travis, R. C.; Tipper, S. J.; Overvad, K.; Grønbæk, H.; Tjønneland, A.; Johnsen, N. F.; Rinaldi, S.; Kaaks, R.; Lukanova, A.; Boeing, H.; Aleksandrova, K.; Trichopoulou, A.; Trichopoulos, D.; Andarakis, G.; Palli, D.; Krogh, V.; Tumino, R.; Sacerdote, C.; Bueno-de-Mesquita, H. B.; Arguelles, M. V.; Sánchez, M. J.; Chirlaque, M. D.; Barricarte, A.; Larranaga, N.; González, C. A.; Stattin, P.; Johansson, M.; Khaw, K. T.; Wareham, N.; Gunter, M.; Riboli, E.; Key, T.
Article Title: Insulin-like growth factor-I concentration and risk of prostate cancer: Results from the European prospective investigation into cancer and nutrition
Abstract: Background: High circulating insulin-like growth factor-I (IGF-I) concentrations have been associated with increased risk for prostate cancer in several prospective epidemiological studies. In this study, we investigate the association between circulating IGF-I concentration and risk of prostate cancer over the long term in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Methods: In a nested case-control design, 1,542 incident prostate cancer cases from eight European countries were individually matched to 1,542 controls by study center, age at recruitment, duration of follow-up, time of day, and duration of fasting at blood collection. Conditional logistic regression models were used to calculate risk for prostate cancer associated with IGF-I concentration, overall and by various subgroups. Results: Circulating IGF-I concentration was associated with a significant increased risk for prostate cancer [OR for highest vs. lowest quartile, 1.69; 95% confidence interval (CI), 1.35-2.13; P trend = 0.0002]. This positive association did not differ according to duration of follow-up [ORs for highest vs. lowest quartile were 2.01 (1.35-2.99), 1.37 (0.94-2.00), and 1.80 (1.17-2.77) for cancers diagnosed <4, 4-7, and >7 years after blood collection, respectively (P heterogeneity = 0.77)] or by stage, grade, and age at diagnosis or age at blood collection (all subgroups P heterogeneity >0.05). Conclusion: In this European population, high circulating IGF-I concentration is positively associated with risk for prostate cancer over the short and long term. Impact: As IGF-I is the only potentially modifiable risk factor so far identified, research into the effects of reducing circulating IGF-I levels on subsequent prostate cancer risk is warranted. ©2012 AACR.
Keywords: adult; controlled study; aged; middle aged; major clinical study; case control study; case-control studies; cancer risk; cancer staging; follow up; cancer diagnosis; cancer grading; prospective study; prospective studies; protein blood level; disease association; logistic models; risk; prostate cancer; prostatic neoplasms; blood sampling; multicenter study; disease duration; age distribution; somatomedin c; insulin-like growth factor i; diet restriction; nutrition; insulin-like growth factor binding protein 3
Journal Title: Cancer Epidemiology Biomarkers and Prevention
Volume: 21
Issue: 9
ISSN: 1055-9965
Publisher: American Association for Cancer Research  
Date Published: 2012-09-01
Start Page: 1531
End Page: 1541
Language: English
DOI: 10.1158/1055-9965.epi-12-0481-t
PROVIDER: scopus
PUBMED: 22761305
PMCID: PMC5749609
DOI/URL:
Notes: --- - "Export Date: 1 October 2012" - "CODEN: CEBPE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Par Erik Stattin
    47 Stattin